Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Tvede is active.

Publication


Featured researches published by Michael Tvede.


Critical Care Medicine | 2006

Procalcitonin increase in early identification of critically ill patients at high risk of mortality.

Jens-Ulrik Jensen; Lars Heslet; Tom Hartvig Jensen; K. Espersen; Peter Steffensen; Michael Tvede

Objective:To investigate day-by-day changes in procalcitonin and maximum obtained levels as predictors of mortality in critically ill patients. Design:Prospective observational cohort study. Setting:Multidisciplinary intensive care unit at Rigshospitalet, Copenhagen University Hospital, a tertiary reference hospital in Denmark. Patients:Four hundred seventy-two patients with diverse comorbidity and age admitted to this intensive care unit. Interventions:Equal in all patient groups: antimicrobial treatment adjusted according to the procalcitonin level. Measurements and Main Results:Daily procalcitonin measurements were carried out during the study period as well as measurements of white blood cell count and C-reactive protein and registration of comorbidity. The primary end point was all-cause mortality in a 90-day follow-up period. Secondary end points were mortality during the stay in the intensive care unit and in a 30-day follow-up period. A total of 3,642 procalcitonin measurements were evaluated in 472 critically ill patients. We found that a high maximum procalcitonin level and a procalcitonin increase for 1 day were independent predictors of 90-day all-cause mortality in the multivariate Cox regression analysis model. C-reactive protein and leukocyte increases did not show these qualities. The adjusted hazard ratio for procalcitonin increase for 1 day was 1.8 (95% confidence interval 1.3–2.7). The relative risk for mortality in the intensive care unit for patients with an increasing procalcitonin was as follows: after 1 day increase, 1.8 (95% confidence interval 1.4–2.4); after 2 days increase, 2.2 (95% confidence interval 1.6–3.0); and after 3 days increase: 2.8 (95% confidence interval 2.0–3.8). Conclusions:A high maximum procalcitonin level and a procalcitonin increase for 1 day are early independent predictors of all-cause mortality in a 90-day follow-up period after intensive care unit admission. Mortality risk increases for every day that procalcitonin increases. Levels or increases of C-reactive protein and white blood cell count do not seem to predict mortality.


Clinical Microbiology and Infection | 2011

Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy

M. Suppli; Rune Aabenhus; Z.B. Harboe; L.P. Andersen; Michael Tvede; Jens-Ulrik Jensen

Enterococcus species are common in nosocomial bloodstream infections and their incidence is rising. Although well recognized in several serious bacterial infections, the influence of appropriate antimicrobial therapy in enterococcal bacteraemia has not been fully settled. The aim of the study was to determine whether administration of inappropriate antibiotics in enterococcal bacteraemia is an independent risk factor for mortality, among other known and suspected risk factors. We conducted a cohort study of E. faecalis/faecium bacteraemia during a 3-year period at a single tertiary care hospital in Denmark. Patients with growth of non-enterococcus co-pathogens apart from the enterococcal bacteraemia were also included, as were patients with repeated enterococcal bacteraemia. Time to appropriate antimicrobial therapy was counted from the first episode. Appropriate antibiotic therapy was defined as any therapy with documented clinical effect, in vitro activity and a minimum treatment length of 6 days. Multivariate regression models were built to determine the independent risk factors for mortality. We included 196 patients with enterococcal bacteraemia. Appropriate antibiotics for at least 6 days were administered in 146 of these (74%). Thirty-day mortality was 26%. Multivariate logistic regression identified independent predictors of 30-day all-cause mortality: appropriate antimicrobial therapy for ≥ 6 days (odds ratio for mortality 0.33, 0.14-0.79), ICU admission (4.2, 1.7-10), thrombocytopenia (3.9, 1.6-9.3), chronic liver failure (3.3, 1.1-10) and age ≥ 60 years (2.2, 0.99-5.0). Antibiotics not appropriately covering enterococci are frequently administered empirically in suspected bloodstream infections. Inappropriate antibiotic therapy was an independent risk factor for mortality in enterococcal bacteraemia.


Annals of Internal Medicine | 2007

Infection Risk with Nitrofurazone-Impregnated Urinary Catheters in Trauma Patients: A Randomized Trial

Jakob Stensballe; Michael Tvede; Dagnia Looms; Freddy Lippert; Benny Dahl; Else Kirstine Tønnesen; Lars S. Rasmussen


Archive | 2007

Infection Risk with Nitrofurazone-Impregnated Urinary Catheters in Trauma Patients

Jakob Stensballe; Michael Tvede; Dagnia Looms; Freddy Lippert; Benny Dahl; Lars S. Rasmussen


Ugeskrift for Læger | 2013

Tarmbakterieflora kan have betydning for glukose- og fedtmetabolisme

Kristian Hallundbæk Mikkelsen; Morten Frost Munk Nielsen; Michael Tvede; Torben Hansen; Jens J. Holst; Tina Vilsbøll; Filip K. Knop; Oluf Pedersen


Ugeskrift for Læger | 2008

The 2nd white coat revolution

Niels Høiby; Helle Krogh Johansen; Michael Tvede; Leif P. Andersen


Critical Care Medicine | 2006

LOWER INFECTION RATE IN TRAUMA PATIENTS WITH NITROFURAZONE-IMPREGNATED URINARY CATHETERS -A RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL.: 560

Jakob Stensballe; Freddy Lippert; Lars S. Rasmussen; Michael Tvede; Benny Dahl; Dagnia Looms; Else Toennesen


Ugeskrift for Læger | 2005

Antibiotic treatment in four departments of a university hospital. A descriptive period prevalence study

Ytting H; Terslev L; Michael Tvede; Heslet L; Høiby N


Ugeskrift for Læger | 2004

Aminoglycosides to critically ill patients

Lars Heslet; Michael Tvede; Jens Schierbeck


Ugeskrift for Læger | 2004

Aminoglykosider til kritisk syge patienter

Lars Heslet; Michael Tvede; Jens Schierbeck

Collaboration


Dive into the Michael Tvede's collaboration.

Top Co-Authors

Avatar

Freddy Lippert

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

Jakob Stensballe

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar

Benny Dahl

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jens Schierbeck

Odense University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lars S. Rasmussen

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar

Niels Høiby

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

Filip K. Knop

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

Jens J. Holst

University of Copenhagen

View shared research outputs
Researchain Logo
Decentralizing Knowledge